Cargando…

Any progress for HIV vaccines to come?

Detalles Bibliográficos
Autor principal:	Wigzell, Hans
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716937/ http://dx.doi.org/10.1186/1742-4690-3-S1-S29

Ejemplares similares

Adolescents with perinatally acquired HIV — coming your way
por: Foster, C
Publicado: (2010)

O014. The diagnostic mistake: when the patient reports pain affecting eyes and benzodiazepines abuse without any glaucoma or any apparent organic cause
por: Nicolodi, Maria, et al.
Publicado: (2015)

Everyday postures in idiopathic scoliosis: is there any correlation with curve morphology?
por: Negrini, A, et al.
Publicado: (2013)

Evolution of progressive multifocal leukoencephalopathy in HIV-infected patients
por: Iancu, Ana Maria, et al.
Publicado: (2014)

Elite control of HIV infection: implications for vaccines
por: Pereyra, Florencia, et al.
Publicado: (2006)

Severity of injury does not have any impact on post traumatic stress symptoms in severely injured patients
por: Quale, Anette Johansen, et al.
Publicado: (2009)

Will our dreams ever come true: treatment options for patients with HAM/TSP in 10 years
por: Pise-Masison, Cynthia
Publicado: (2014)

Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine
por: Billingsley, Peter, et al.
Publicado: (2014)

Toward a glycopeptide-based HIV-1 vaccine
por: Wang, Lai-Xi, et al.
Publicado: (2006)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Vaccination of HIV positive children... a genuine challenge
por: Vlad, Delia Adelina, et al.
Publicado: (2013)

O032. Associations between any headache and obesity: results from a systematic review and meta-analysis of observational studies
por: Degan, Diana, et al.
Publicado: (2015)

Long-term protection of hepatitis B vaccine in HIV-infected patients
por: Biekre, R, et al.
Publicado: (2014)

O078: 6 years of national German hand hygiene campaign-where do we come from and where are we heading to?
por: Reichardt, C, et al.
Publicado: (2013)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali
por: Poole, D, et al.
Publicado: (2012)

Complement supports progression of HIV and turns neutralising antibodies at low concentration into infection enhancing antibodies
por: Dierich, Manfred P, et al.
Publicado: (2006)

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study
por: Viard, JP, et al.
Publicado: (2010)

Significant protection from infection and AIDS progression after gastrointestinal and oral vaccinations, respectively, with a SIV DNA/rMVA vaccine
por: Aldovini, A, et al.
Publicado: (2012)

Increased immunogenicity of HIV vaccination with constant-current electroporation and molecular adjuvants in mice and rhesus macaques
por: Hirao, Lauren, et al.
Publicado: (2006)

Novel strategy for generation of mucosal immune responses against HIV-1 following systemic vaccination
por: Kutzler, Michele A, et al.
Publicado: (2006)

OA031-03. Increased regulatory T cell frequency and HIV-1 specific suppression after therapeutic vaccination of HIV-infected patients on antiretroviral therapy
por: Macatangay, BC, et al.
Publicado: (2009)

HLA-A*0201-specific epitopes of Indian HIV-1C as candidates for vaccine design
por: Sundaramurthi, Jagadish Chandrabose, et al.
Publicado: (2012)

Design of lipid nanoparticle delivery agents for multivalent display of recombinant Env trimers in HIV vaccination
por: Pejawar-Gaddy, S, et al.
Publicado: (2012)

Measuring force of infection and vaccine effects on transmission stages in clinical trials of experimental malaria vaccines
por: Felger, Ingrid, et al.
Publicado: (2012)

A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
por: Jackson, AG, et al.
Publicado: (2012)

Coordinated changes of HIV-1 Gag and Env during assembly and maturation
por: Kräusslich, Hans-Georg
Publicado: (2013)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
por: Andersen-Nissen, E, et al.
Publicado: (2012)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
por: Phogat, SK, et al.
Publicado: (2009)

Shaping humoral responses against mini-libraries of HIV env antigens via lipid nanoparticle vaccine delivery
por: Hanson, MC, et al.
Publicado: (2012)

Alterations in function and distribution of regulatory T Cells (Tregs) may blunt vaccine induced immune responses in HIV infection
por: van Lunzen, J, et al.
Publicado: (2012)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

OA021-03. Design and development of DNA vaccines for the co-expression of micro-RNA and HIV-1 Env
por: Wheatley, AK, et al.
Publicado: (2009)

Beneficial HLA-mediated viral polymorphisms on the transmitted virus additively influence disease progression in HIV-1, subtype C infection
por: Ntale, RS, et al.
Publicado: (2012)

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania
por: Koehler, RN, et al.
Publicado: (2009)

Minimally invasive and surface electroporation delivery of DNA vaccines for the induction of robust humoral immune responses against HIV antigens
por: Sardesai, NY, et al.
Publicado: (2012)

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
por: Rolland, M, et al.
Publicado: (2009)

Hyperglycemia During Acute Spinal Cord Injury Is a Detrimental Factor That Impairs Functional Improvement in Acute C3-C4 Cervical Cord Injury Patients Without Any Bony Damages
por: Kubota, K, et al.
Publicado: (2015)

Vaccine responses to conserved regions of the HIV-1 proteome are associated with an increased capacity to inhibit multiple virus isolates ex vivo
por: Ashraf, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fv520654jqvrruc4512et0r26h